CDKN2A Variants in a Population-Based Sample of Queensland Families With Melanoma
Open Access
- 3 March 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 91 (5) , 446-452
- https://doi.org/10.1093/jnci/91.5.446
Abstract
BACKGROUND: Mutations in the CDKN2A gene confer susceptibility to cutaneous malignant melanoma (CMM); however, the population incidence of such mutations is unknown. Polymorphisms in CDKN2A have also been described, but it is not known whether they influence melanoma risk. We investigated the association of CDKN2A mutations and polymorphisms with melanoma risk in a population-based sample of families ascertained through probands with melanoma. METHODS: The 482 Queensland, Australia, families in our sample were characterized previously as having high, intermediate, or low family risk of CMM. Unrelated individuals (n = 200 families/individuals) drawn from the Australian Twin Registry served as control subjects. For individuals in the high-risk group, the entire CDKN2A gene coding region was screened for mutations by use of the polymerase chain reaction, agarose gel electrophoresis, allele-specific oligonucleotide (ASO) hybridization, and single-strand conformation polymorphism analysis. The intermediate- and low-risk families and control subjects were analyzed by ASO hybridization for a total of six recurring mutations as well as for polymorphisms at nucleotides (Nts) 442, 500, and 540. RESULTS: CDKN2A mutations were found only in the high-risk families (nine [10.3%] of 87). The prevalence of the Nt500G (guanosine) polymorphism increased linearly with increasing familial risk (two-sided P = .02) and was highest in the nine (primarily Celtic) families with CDKN2A mutations. After adjustment for ethnic origin, the relationship between risk group and the frequency of the Nt500G allele was weakened ( P = .25); however, there was no relationship between ethnic origin and Nt500-polymorphism frequency among the control subjects. CONCLUSIONS: CDKN2A mutations are rare in this population (approximately 0.2% of all melanoma cases in Queensland) and appear to be associated with melanoma in only the most affected families. The Nt500G allele appears to be associated with familial risk, but this association probably reflects Celtic ancestry.Keywords
This publication has 33 references indexed in Scilit:
- Virus, cells and videotapeNature Medicine, 2002
- Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in Hum Mol Genet 1998 May;7(5):941]Human Molecular Genetics, 1998
- Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindredsOncogene, 1997
- Germline Mutations of the CDKN2 Gene in UK Melanoma FamiliesHuman Molecular Genetics, 1997
- Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.Proceedings of the National Academy of Sciences, 1996
- Familial Melanoma and Pancreatic CancerNew England Journal of Medicine, 1996
- Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds withp16INK4MutationsNew England Journal of Medicine, 1995
- Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindredsHuman Molecular Genetics, 1995
- CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome familiesMelanoma Research, 1995
- Germline p16 mutations in familial melanomaNature Genetics, 1994